|1.||Xie, Yao: 6 articles (07/2007 - 02/2004)|
|2.||Escudier, Bernard: 4 articles (05/2010 - 12/2007)|
|3.||Zeuzem, Stefan: 4 articles (01/2009 - 12/2002)|
|4.||Xu, Dao-zhen: 4 articles (07/2007 - 02/2004)|
|5.||Chung, Raymond T: 3 articles (12/2010 - 07/2004)|
|6.||Ravaud, Alain: 3 articles (05/2010 - 12/2007)|
|7.||Lu, Zhi-meng: 3 articles (07/2007 - 02/2004)|
|8.||Li, Ming-hui: 3 articles (07/2007 - 08/2006)|
|9.||Wang, Yu-ming: 3 articles (07/2007 - 02/2004)|
|10.||Zhang, Shu-lin: 3 articles (07/2007 - 02/2004)|
|1.||Chronic Hepatitis C
01/01/1997 - "[The therapeutic efficacy of interferon-alfa-2a (Roferon-A) in chronic hepatitis C]."
03/01/1999 - "Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients."
12/01/1996 - "A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C."
06/01/1996 - "Randomized trial comparing three different regimens of interferon alfa 2a in chronic hepatitis C."
08/01/2006 - "The patients with chronic hepatitis C were treated with PEG-IFN alpha -2a and Roferon-A for 24 weeks. "
|2.||Renal Cell Carcinoma (Grawitz Tumor)
07/01/1993 - "Three trials were conducted to define the efficacy and toxicity of interferon alfa-2a in the treatment of metastatic renal cell cancer. "
07/01/1993 - "Interferon alfa-2a had minimal antitumor activity in patients with advanced renal cell carcinoma and long-term survival was achieved in a small proportion of patients. "
07/01/1993 - "Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up."
12/01/1988 - "Eighteen patients with advanced renal cell carcinoma were treated with recombinant interferon alpha-2a (18 million IU s.c. "
01/01/1987 - "This methodology was evaluated during a clinical trial of recombinant interferon alfa-2a (rIFN alfa-2a) for the treatment of 10 metastatic renal cell carcinoma patients. "
06/01/2004 - "Because of lack of in vivo antiviral activity against BVDV, recombinant human interferon alfa-2a has little promise as a therapeutic agent for the treatment of BVDV infection, at least in persistently infected cattle. "
11/15/2001 - "Early use of interferon alfa-2a can stop HCV infection."
01/01/1995 - "The other 30 patients with recurrent or multiorgan infections received 3 courses with 12 x 10(6) IU interferon alfa-2a subcutaneously. "
10/01/1993 - "Treatment of respiratory syncytial virus infection with recombinant interferon alfa-2a."
02/01/1987 - "Changes of hepatitis B virus (HBV) markers during prolonged recombinant interferon alpha-2A treatment of chronic HBV infection."
04/15/1986 - "A Phase II study was then conducted in 641 patients to evaluate the efficacy of interferon alfa-2a in a number of disseminated malignant neoplasms. "
07/01/1997 - "Moreover, this interaction appeared to be closely associated with a soluble factor produced by the tumor T-cell infiltrate and was at least partially blocked by interferon alfa-2a."
11/01/1996 - "The use of interferon alfa-2a for 9 months stopped progression of the tumor."
01/01/1995 - "Patients with bidimensionally measurable disease were treated with Roferon-A 1 million units subcutaneously daily and tumor assessments were conducted on a monthly basis. "
08/01/1993 - "Intralesional interferon alfa-2a (IFN alfa-2a) has been shown to have activity against different epithelial tumors and to have an antiviral effect. "
10/01/1991 - "This study was designed to evaluate the therapeutic efficacy and toxicity of recombinant interferon alpha-2a (rIFN alfa-2a) given as initial systemic therapy in untreated mycosis fungoides and/or Sezary's syndrome patients, at a slowly escalating schedule up to the maximal tolerated dose. "
01/01/1995 - "To investigate the efficacy of combined topical therapy and systemic interferon alfa-2a in patients with mycosis fungoides (MF) and the Sézary syndrome (SS). "
01/01/1990 - "We previously demonstrated that recombinant interferon alfa-2a (IFN-alfa) in a dose of 50 X 10(6) U million units (MU)/m2 intramuscularly (IM) three times per week has efficacy against mycosis fungoides (MF) and the Sézary syndrome (SS). "
01/01/1990 - "Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome."
06/24/1989 - "Autoimmune haemolytic anaemia associated with interferon alfa-2a in a patient with mycosis fungoides."
|2.||Interferon Alfa-2a (Interferon Alfa 2a)
|5.||Leucovorin (Folinic Acid)
|6.||Interferon-alpha (Interferon Alfa)
|7.||peginterferon alfa-2a (Pegasys)
|9.||Interferon Alfa-2b (Interferon Alfa 2b)
|2.||Drug Therapy (Chemotherapy)
|4.||Bone Marrow Transplantation (Transplantation, Bone Marrow)